AEON Raises $6M in PIPE, Cuts Debt 90% and Advances BOTOX® Biosimilar
AEON strengthened its balance sheet with $6 million PIPE financing and a Daewoong note exchange that cut outstanding debt by over 90%. The company reported full-year 2025 results, positive FDA BPD Type 2a feedback, and analytical tests confirming 100% amino-acid sequence match for ABP-450 biosimilar to BOTOX®.
1. Financial Performance and Balance Sheet Strengthening
AEON reported cash and cash equivalents of $3.0 million as of December 31, 2025, excluding an additional $4.2 million from the second PIPE closing. The company completed a $6 million PIPE financing and a Daewoong Pharmaceutical note exchange, reducing outstanding debt by over 90% and extending runway into the third quarter of 2026.
2. Positive Comparative Analytical Results
In November 2025, AEON confirmed 100% amino-acid sequence identity across more than 3,400 residues in ABP-450 versus BOTOX®, with LC/MS sequence coverage of 93–99% across all five proteins. Functional analyses demonstrated comparable potency in LD50 and cell-based assays, consistent composition via vial-to-vial ELISA, and equivalent enzymatic cleavage of SNAP-25.
3. Constructive FDA BPD Type 2a Meeting Feedback
The FDA’s BPD Type 2a meeting validated AEON’s 351(k) analytical similarity strategy, noting its methodologies as reasonable for advancing the biosimilar program. The feedback provides a clear framework for completing the analytical comparability package and sets the stage for a Type 2b meeting in 2026 to discuss clinical and regulatory pathways for full-label U.S. approval.
4. Leadership Appointment and Next Steps
In March 2026, AEON appointed John Bencich as Chief Financial Officer, bringing over 25 years of capital markets and strategic leadership experience. With foundational biosimilarity data and regulatory clarity, the company plans to complete its analytical comparability program in 2026 and pursue U.S. market entry for ABP-450.